Investigational drug · Phase 3
Cretostimogene Grenadenorepvec
Also called: CG0070
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer, Urologic Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
5
Any phase or sponsor naming "Cretostimogene Grenadenorepvec"
First trial start
2020
Oct 27, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Cretostimogene Grenadenorepvec", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non Muscle Invasive Bladder Cancer
- High-grade Ta/ T1 Papillary Disease Bladder Cancer
- Urologic Cancer
- Bladder Cancer
- Urothelial Carcinoma
- High-Risk Non-Muscle-Invasive Bladder Cancer
Approved drugs for the same conditions: Bladder and urothelial cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Cretostimogene Grenadenorepvec" as an intervention, largest first.
- A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBTPivotal-lookingActive, not recruiting
CG Oncology, Inc.Industry
NCT06111235 · 367 participants · Start Dec 14, 2023 · Primary completion Nov 2026
Drug: Cretostimogene Grenadenorepvec · For: Non Muscle Invasive Bladder Cancer; Urologic Cancer; Bladder Cancer and 1 more
Sites: Homewood, Alabama; Gilbert, Arizona; Scottsdale, Arizona · 95 sites in all
- Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBCPivotal-lookingRecruiting
CG Oncology, Inc.Industry
NCT06567743 · 325 participants (planned) · Start Sep 16, 2024 · Primary completion Mar 31, 2027
Drug: Cretostimogene Grenadenorepvec · For: High-Risk Non-Muscle-Invasive Bladder Cancer
Sites: Gilbert, Arizona; Phoenix, Arizona; Tucson, Arizona · 80 sites in all
- Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-GuerinPivotal-lookingActive, not recruiting
CG Oncology, Inc.Industry
NCT04452591 · 190 participants (planned) · Start Oct 27, 2020 · Primary completion Jun 16, 2030
Drug: Cretostimogene Grenadenorepvec · For: Non Muscle Invasive Bladder Cancer; High-grade Ta/ T1 Papillary Disease Bladder Cancer
Sites: Homewood, Alabama; Phoenix, Arizona; Tucson, Arizona · 86 sites in all
Lepu Biopharma Co., Ltd.Industry
NCT07283835 · 16 participants (planned) · Start Dec 4, 2025 · Primary completion Dec 31, 2027
Drug: Cretostimogene Grenadenorepvec · For: Non Muscle Invasive Bladder Cancer; High-grade Ta/ T1 Papillary Disease Bladder Cancer
Sites: Beijing, China; Chongqing, China; Fuzhou, China · 14 sites in all
CG Oncology, Inc.Industry
NCT06443944
Drug: Cretostimogene Grenadenorepvec · For: Non-Muscle Invasive Bladder Cancer; Urothelial Carcinoma; Urologic Cancer and 1 more
Sites: Gilbert, Arizona; Bakersfield, California; Los Angeles, California · 27 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Trial design drives outcomes: harmonising efficacy across BCG-unresponsive bladder carcinoma in situ trials.
Robesti D, Kamat AM, Ploussard G, et al. · BJU Int 2026
- Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.
Tyson MD, Nam JK, Joshi SS, et al. · Lancet Oncol 2026
- Cretostimogene grenadenorepvec: promise beyond response.
Robesti D, Fallara G, Martini A · Lancet Oncol 2026
- Immunotherapy in bladder cancer: a systematic review of clinical trials and therapeutic advances.
Alasker A, Alghafees M, Nammor T, et al. · BMC Urol 2026
- Advances in intravesical therapy for non-muscle-invasive bladder cancer.
Tang Y, Wang L, Liu H, et al. · Crit Rev Oncol Hematol 2026
- Decoding Immune Mechanisms in BCG-unresponsive Non-muscle Invasive Bladder Cancer.
Abou Chakra M, Duquesne I, O'Donnell MA · Front Biosci (Landmark Ed) 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.